Attovia Therapeutics, a clinical-stage biopharmaceutical company, priced its upsized initial public offering at $17 per share, selling 17 million shares to raise approximately $289 million before expenses. The company focuses on developing next-generation biotherapeutics for immune-mediated diseases with high unmet needs. Attovia's stock is set to begin trading on Nasdaq under the symbol 'ATTO' on August 5, 2026. The funds will support ongoing development of its lead drug candidates targeting chronic pruritic diseases, atopic dermatitis, and inflammatory bowel disease.
Whale wallets have accumulated about 1.54 billion XRP tokens worth $2.2 billion in 96 hours, signaling strong investor confidence as XRP trades near $1.41. This large-scale buying reduces XRP's circulating supply, potentially supporting higher prices...
BlackRock reports Bitcoin volatility has dropped from about 80 to 35-40, driven by ETFs, options, deeper liquidity, and long-term holders. Large Bitcoin holders increasingly use Bitcoin ETFs like BlackRock's IBIT to access collateralized borrowing, h...
The SEC's new five-year Innovation Exemption allows trading of tokenized U.S. stocks on public blockchains with shareholder rights equal to traditional shares. This framework could open new revenue streams for companies like Coinbase, Robinhood, and ...
Solana (SOL) is showing strong momentum in October, leading large-cap altcoins with a 9% weekly gain and breaking key resistance levels. Its relative demand is increasing compared to Ethereum and Bitcoin, supported by fresh institutional inflows into...
XRP has surpassed the $1.40 mark, signaling renewed investor interest as the XRP Ledger (XRPL) broadens its financial ecosystem beyond payments. The recent XRPL 3.4.0 upgrade introduced a lending framework supporting fixed-term, uncollateralized loan...
